Oxford BioMedicaOXBDF 71 14-Day RSI is 43.21 as of Jul. 03, 2026. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $6.62 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,423 Biotechnology companies, Oxford BioMedica ranks worse than 80.11% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-03), Oxford BioMedica's 14-Day RSI is 43.21.
The industry rank for Oxford BioMedica's 14-Day RSI or its related term are showing as below:
OXBDF's 14-Day RSI is ranked worse than 80.11% of 1423
companies
in the Biotechnology industry
Industry Median: 49.99
vs OXBDF: 43.21
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Oxford BioMedica 14-Day RSI Related Terms
OXBDF vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Oxford BioMedica's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (OXBDF) has a 14-Day RSI of 43.21 as of Jul. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #1140 out of 1423 companies in the Biotechnology industry, placing it in the top 80.1%.
Is Oxford BioMedica's 14-Day RSI too high?
Oxford BioMedica's current 14-Day RSI is 43.21. The Biotechnology industry median 14-Day RSI is 49.99. Oxford BioMedica's value of 43.21 is 13.6% below this industry median. Based on the distribution chart, Oxford BioMedica ranks #1140 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #1140 out of 1423 companies for 14-Day RSI. This places Oxford BioMedica in the lower half of its industry. The industry median 14-Day RSI is 49.99. Oxford BioMedica's value of 43.21 is 13.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioMedica's current 14-Day RSI of 43.21 is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current 14-Day RSI is 43.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.62, compared to a current price of $7.93 — trading 19.7% above its estimated fair value. The current 14-Day RSI is 43.21 and 13.6% below the Biotechnology industry median of 49.99. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current 14-Day RSI is 43.21 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.93 is trading 19.7% above its estimated GF Value™ of $6.62.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for OXBDF:
14-Day RSI: 43.21
GF Value™: $6.62 vs. price of $7.93 (19.7% above fair value)
Industry Position: 13.6% below the Biotechnology median (#1140 of 1423)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score
Get the complete analysis for OXBDF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 